ACLAX | VEVYX | ACLAX / VEVYX | |
Total Expense Ratio | 1.23 | 0.66 | 186% |
Annual Report Gross Expense Ratio | 1.23 | 0.66 | 186% |
Fund Existence | 21 years | 13 years | - |
Gain YTD | 6.820 | 1.133 | 602% |
Front Load | 6% | N/A | - |
Min. Initial Investment | 2500 | 1000000 | 0% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 7B | 17.2B | 41% |
Annual Yield % from dividends | 1.30 | 1.08 | 121% |
Returns for 1 year | 1.31 | -7.20 | -18% |
Returns for 3 years | 0.86 | -2.80 | -31% |
Returns for 5 years | 14.85 | 34.80 | 43% |
Returns for 10 years | 11.27 | 45.03 | 25% |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
FTXH | 27.57 | 0.21 | +0.79% |
First Trust Nasdaq Pharmaceuticals ETF | |||
HACK | 82.90 | 0.47 | +0.57% |
Amplify Cybersecurity ETF | |||
IGBH | 24.48 | 0.06 | +0.25% |
iShares Interest Rate Hdg L/T Corp BdETF | |||
SCDS | 56.45 | N/A | N/A |
JPMorgan Fundamental Data Sci Sm Cor ETF | |||
HIO | 3.94 | -0.02 | -0.51% |
Western Asset High Income Opportunity Fund |